1.
Cutis
; 42(3): 238-40, 1988 Sep.
Artículo
en Inglés
| MEDLINE
| ID: mdl-3048914
RESUMEN
Naftifine, a member of a new class of synthetic antifungal drugs, the allylamines, was evaluated for the treatment of cutaneous candidiasis. In a double-blind, parallel-group clinical trial, sixty patients with cutaneous candidiasis were randomly assigned to receive either naftifine cream 1 percent or its vehicle twice a day for three weeks. Two weeks after the end of therapy, 77 percent of the naftifine-treated patients were mycologically cured (negative results on potassium hydroxide preparations and culture) and had no clinically apparent disease, compared with 3 percent of the patients treated with vehicle (p less than 0.001). Side effects reported with naftifine cream were few and minor.
Asunto(s)
Alilamina/administración & dosificación , Aminas/administración & dosificación , Antifúngicos/administración & dosificación , Candidiasis Cutánea/tratamiento farmacológico , Adolescente , Adulto , Anciano , Alilamina/efectos adversos , Alilamina/análogos & derivados , Alilamina/uso terapéutico , Antifúngicos/efectos adversos , Antifúngicos/uso terapéutico , Ensayos Clínicos como Asunto , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pomadas
2.
J Am Acad Dermatol
; 29(4): 646-8, 1993 Oct.
Artículo
en Inglés
| MEDLINE
| ID: mdl-8408803